These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38178285)

  • 1. UK PID Patients: Overview of perception on IgRT and infections using short survey.
    Hodkinson JP; Griffiths PR; Narme AMI; Staiger C
    Pharmazie; 2023 Dec; 78(11):231-237. PubMed ID: 38178285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
    Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
    Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
    Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
    Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
    Grigoriadou S; Clubbe R; Garcez T; Huissoon A; Grosse-Kreul D; Jolles S; Henderson K; Edmonds J; Lowe D; Bethune C
    Clin Exp Immunol; 2022 Oct; 210(1):1-13. PubMed ID: 35924867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
    Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
    J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
    Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
    Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.
    Wasserman RL
    Allergy Asthma Proc; 2021 Nov; 42(6):489-494. PubMed ID: 34871156
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
    Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
    Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation.
    Baumann U; Routes JM; Soler-Palacín P; Jolles S
    Front Immunol; 2018; 9():1837. PubMed ID: 30147696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of immunoglobulin replacement therapy in secondary immunodeficiency to hematological cancer: a single center observational study.
    Guerola LDC; Sacristán AAG; Portolés A; Jasso M; Guerra-Galán T; de la Fuente-Munoz E; Palacios-Ortega M; Fernández-Arquero M; Cuesta-Mínguez C; Rodríguez-Sanz A; Peña-Cortijo A; Polo M; Morales MM; Anguita-Mandly E; Benítez Jiménez T; Benavente Cuesta C; Sánchez-Ramón S
    Front Immunol; 2024; 15():1413231. PubMed ID: 38989286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy.
    Gernez Y; Baker MG; Maglione PJ
    Transfusion; 2018 Dec; 58 Suppl 3(Suppl 3):3056-3064. PubMed ID: 30536429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.
    Edgar JDM; Richter AG; Huissoon AP; Kumararatne DS; Baxendale HE; Bethune CA; Garcez T; Misbah SA; Sorensen RU;
    J Clin Immunol; 2018 Feb; 38(2):204-213. PubMed ID: 29423883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK.
    Shields AM; Anantharachagan A; Arumugakani G; Baker K; Bahal S; Baxendale H; Bermingham W; Bhole M; Boules E; Bright P; Chopra C; Cliffe L; Cleave B; Dempster J; Devlin L; Dhalla F; Diwakar L; Drewe E; Duncan C; Dziadzio M; Elcombe S; Elkhalifa S; Gennery A; Ghanta H; Goddard S; Grigoriadou S; Hackett S; Hayman G; Herriot R; Herwadkar A; Huissoon A; Jain R; Jolles S; Johnston S; Khan S; Laffan J; Lane P; Leeman L; Lowe DM; Mahabir S; Lochlainn DJM; McDermott E; Misbah S; Moghaddas F; Morsi H; Murng S; Noorani S; O'Brien R; Patel S; Price A; Rahman T; Seneviratne S; Shrimpton A; Stroud C; Thomas M; Townsend K; Vaitla P; Verma N; Williams A; Burns SO; Savic S; Richter AG
    Clin Exp Immunol; 2022 Sep; 209(3):247-258. PubMed ID: 35641155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7th International Immunoglobulin Conference: Immunodeficiencies.
    Schmidt RE; Ochs HD
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):3-4. PubMed ID: 25546741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.
    Warnatz K; Jolles S; Agostini C; Vianello F; Borte M; Bethune C; Grigoriadou S; Richter A; Jain R; Lowe DM; Katelaris C; Milito C; Cook MC
    Clin Immunol; 2022 Mar; 236():108938. PubMed ID: 35121105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.
    Soshnick SH; Joseph T; Bennett NJ
    J Clin Immunol; 2021 Aug; 41(6):1208-1212. PubMed ID: 33740168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
    Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
    Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the treatment of primary immunodeficiencies.
    García JM; Español T; Gurbindo MD; Casas C C
    Allergol Immunopathol (Madr); 2007; 35(5):184-92. PubMed ID: 17923072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.